Omentin-1 vs Larazotide
Head-to-head comparison of Omentin-1 (Omentin-1 (Intelectin-1, ITLN1)) and Larazotide (Larazotide acetate (AT-1001)) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | Omentin-1 | Larazotide |
|---|---|---|
| Category | Diabetes & Metabolic | Gastrointestinal |
| Full Name | Omentin-1 (Intelectin-1, ITLN1) | Larazotide acetate (AT-1001) |
| Molecular Weight | ~35 kDa | N/A |
| Half-Life | hours | short; designed for local gut action |
| Amino Acids | 313 | 8 |
| Typical Dose | No approved human dose; research use only | 0.5-4 mg TID (clinical studies) |
| Route | IV|SC | Oral |
| Purity | ≥98% | ≥98% |
| Studies Count | 82 | 40 |
| Research Status | Pre-clinical | Clinical |
Omentin-1 Benefits
- ✓insulin sensitivity
- ✓glucose uptake
- ✓lipid handling
Larazotide Benefits
- ✓tight-junction-support
- ✓reduced-permeability
- ✓symptom-reduction
- ✓barrier-protection
Omentin-1 Dosing
not established|not established
Larazotide Dosing
0.5-4 mg orally before meals in clinical trials|typically three times daily|short-course or chronic study protocols
Omentin-1 Side Effects
- ⚠unknown
- ⚠immunogenicity risk
Larazotide Side Effects
- ⚠headache
- ⚠nausea
- ⚠abdominal discomfort
Research Overview
Omentin-1
Lower omentin-1 levels are often associated with obesity, insulin resistance, and metabolic syndrome. Research continues on its use as a biomarker and as a mechanistic lead for AMPK-linked metabolic interventions.
Larazotide
Clinical and translational studies suggest larazotide can reduce antigen passage across the epithelium and improve gut barrier function. It is one of the better-known peptides for intestinal permeability and barrier-focused gastrointestinal therapy.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.